About NeuroDerm (NASDAQ:NDRM)
NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson's disease, as well as other CNS diseases. The Company's Parkinson's disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages. Its liquid LD/CD and apomorphine formulations include ND0612H, ND0612L and ND0701. It is developing ND0612H for the treatment of patients suffering from severe Parkinson's disease. It is developing ND0612L for the treatment of patients at the moderate stage of Parkinson's disease that can no longer control motor complications with oral levodopa. It has also designed ND0701, which is an apomorphine-based product. ND0701 is for patients suffering from Parkinson's disease, may be used mostly by patients suffering from high motor fluctuations and not responding well to LD/CD.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:NDRM
- CUSIP: N/A
- Web: www.neuroderm.com
- Market Cap: $1.02354 billion
- Outstanding Shares: 26,346,000
- 50 Day Moving Avg: $38.84
- 200 Day Moving Avg: $32.05
- 52 Week Range: $15.20 - $38.95
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -23.55
- P/E Growth: -0.82
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $4.87 per share
- Price / Book: 7.98
- EBITDA: ($49,040,000.00)
- Return on Equity: -38.82%
- Return on Assets: -36.88%
- Current Ratio: 17.69%
- Quick Ratio: 17.69%
- Average Volume: 822,422 shs.
- Beta: 0.77
- Short Ratio: 1.47
Frequently Asked Questions for NeuroDerm (NASDAQ:NDRM)
What is NeuroDerm's stock symbol?
NeuroDerm trades on the NASDAQ under the ticker symbol "NDRM."
How were NeuroDerm's earnings last quarter?
NeuroDerm Ltd. (NASDAQ:NDRM) issued its quarterly earnings data on Thursday, May, 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.38) by $0.13. View NeuroDerm's Earnings History.
When will NeuroDerm make its next earnings announcement?
Where is NeuroDerm's stock going? Where will NeuroDerm's stock price be in 2017?
8 analysts have issued 1-year price targets for NeuroDerm's shares. Their predictions range from $39.00 to $70.00. On average, they anticipate NeuroDerm's share price to reach $45.86 in the next year. View Analyst Ratings for NeuroDerm.
What are analysts saying about NeuroDerm stock?
Here are some recent quotes from research analysts about NeuroDerm stock:
- 1. According to Zacks Investment Research, "Neuroderm Ltd. is a clinical-stage pharmaceutical company. It is developing next-generation treatments for central nervous system (CNS) disorders. The Company develops liquid levodopa (LD), which is a treatment for Parkinson's disease (PD). Its product pipelines includes ND0612L for moderate PD, ND0612H for severe PD, ND0680 for severe PD, ND0701 for severe PD and ND0801for Cognitive Disorders. NeuroDerm Ltd. is headquartered in Rehovot, Israel. " (10/18/2017)
- 2. Cowen and Company analysts commented, "Neuroderm announced the preliminary Phase II results for ND0612H, and importantly, the initial feedback from our consultants has been very positive. In general, our consultants believe the efficacy looks comparable to Duodopa, but with a significantly improved use and safety profile. These data substantially de-risk the program. The current valuation is dramatically understated." (3/1/2017)
Are investors shorting NeuroDerm?
NeuroDerm saw a increase in short interest during the month of September. As of September 15th, there was short interest totalling 1,221,573 shares, an increase of 28.1% from the August 31st total of 953,489 shares. Based on an average daily volume of 530,756 shares, the days-to-cover ratio is currently 2.3 days. Currently, 6.0% of the company's stock are sold short.
Who are some of NeuroDerm's key competitors?
Some companies that are related to NeuroDerm include Acceleron Pharma (XLRN), Intercept Pharmaceuticals (ICPT), NovoCure Limited (NVCR), AnaptysBio (ANAB), Radius Health (RDUS), Five Prime Therapeutics (FPRX), MyoKardia (MYOK), Ascendis Pharma A/S (ASND), Clinigen Group PLC (CLIN), Dynavax Technologies Corporation (DVAX), Acorda Therapeutics (ACOR), Sangamo Therapeutics (SGMO), Epizyme (EPZM), Lexicon Pharmaceuticals (LXRX), Dermira (DERM), Xencor (XNCR), REGENXBIO (RGNX) and Athenex (ATNX).
Who are NeuroDerm's key executives?
NeuroDerm's management team includes the folowing people:
- Robert Taub, Chairman of the Board
- Oded S. Liebermann, Chief Executive Officer, Director
- Roy Golan CPA, Chief Financial Officer
- Tami Yardeni, Chief Operating Officer
- Sharon Cohen-Vered Ph.D., Vice President - CMC & QA
- Sheila Oren, Vice President - Clinical and Regulatory Affairs
- Eran Shor, Vice President - Devices
- Oron Yacoby-Zeevi, Vice President - Research & Development
- Revital Mandil-Levin Ph.D., Head - Business Development
- Shmuel Cabilly, Director
When did NeuroDerm IPO?
(NDRM) raised $45 million in an initial public offering on Friday, November 14th 2014. The company issued 4,500,000 shares at a price of $10.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Oppenheimer and Roth Capital Partners were co-managers.
How do I buy NeuroDerm stock?
Shares of NeuroDerm can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NeuroDerm's stock price today?
MarketBeat Community Rating for NeuroDerm (NASDAQ NDRM)MarketBeat's community ratings are surveys of what our community members think about NeuroDerm and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of NeuroDerm stock can currently be purchased for approximately $38.85.
Consensus Ratings for NeuroDerm (NASDAQ:NDRM) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||3 Hold Ratings, 5 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.63)|
|Consensus Price Target: ||$45.86 (18.04% upside)|Consensus Price Target History for NeuroDerm (NASDAQ:NDRM)
Analysts' Ratings History for NeuroDerm (NASDAQ:NDRM)
(Data available from 10/19/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/14/2017||Jefferies Group LLC||Reiterated Rating||Buy||$42.00||Low|
|8/2/2017||Roth Capital||Downgrade||Buy -> Neutral||$33.00 -> $39.00||Low|
|7/24/2017||Raymond James Financial, Inc.||Downgrade||Outperform -> Market Perform||$39.00||High|
|7/21/2017||Deutsche Bank AG||Initiated Coverage||Buy -> Buy||$47.00||High|
|6/14/2017||CIBC||Upgrade||Market Perform -> Outperform||$42.00||High|
|6/14/2017||Oppenheimer Holdings, Inc.||Upgrade||Market Perform -> Outperform||$42.00||High|
|3/7/2017||Citigroup Inc.||Downgrade||Outperform -> Market Perform||N/A|
|3/1/2017||Cowen and Company||Boost Price Target||Outperform||$38.00 -> $70.00||N/A|
Earnings History for NeuroDerm (NASDAQ:NDRM)Earnings History by Quarter for NeuroDerm (NASDAQ NDRM)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2017|| || || || || || || || |
Earnings Estimates for NeuroDerm (NASDAQ:NDRM)
2017 EPS Consensus Estimate: ($1.96)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for NeuroDerm (NASDAQ:NDRM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for NeuroDerm (NASDAQ:NDRM)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for NeuroDerm (NASDAQ:NDRM)
Latest Headlines for NeuroDerm (NASDAQ:NDRM)
|Mitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDerm - GlobeNewswire (press release)|
globenewswire.com - October 19 at 6:40 AM
|Mitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDerm|
feeds.benzinga.com - October 18 at 4:46 AM
|Zacks: Analysts Expect NeuroDerm Ltd. (NDRM) Will Post Earnings of -$0.52 Per Share|
www.americanbankingnews.com - October 15 at 12:08 AM
|Zacks Investment Research Downgrades Neuroderm Ltd (NDRM) to Sell|
www.americanbankingnews.com - October 8 at 11:50 PM
|Critical Review: NeuroDerm (NDRM) versus Its Competitors|
www.americanbankingnews.com - October 2 at 2:22 AM
|NeuroDerm Ltd. (NDRM) Given Average Recommendation of "Buy" by Analysts|
www.americanbankingnews.com - September 30 at 10:42 AM
|NeuroDerm Ltd. (NDRM) Short Interest Update|
www.americanbankingnews.com - September 30 at 3:26 AM
|NeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation - GlobeNewswire (press release)|
globenewswire.com - September 14 at 8:11 AM
|NeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation|
finance.yahoo.com - September 13 at 7:01 AM
|NeuroDerm Ltd. (NDRM) Given Average Rating of "Buy" by Analysts|
www.americanbankingnews.com - September 5 at 10:44 AM
|NeuroDerm Ltd. (NDRM) Short Interest Down 29.2% in August|
www.americanbankingnews.com - August 29 at 1:06 AM
|Stocks Under Scanner in the Biotech Space -- Merrimack Pharma, MannKind, NeuroDerm, and Celsion - PR Newswire (press release)|
www.prnewswire.com - August 23 at 9:05 AM
|Equities Analysts Offer Predictions for NeuroDerm Ltd.'s Q3 2017 Earnings (NDRM)|
www.americanbankingnews.com - August 18 at 6:42 AM
|NeuroDerm Ltd. (NASDAQ:NDRM) Rating Reiterated by Jefferies Group LLC|
www.americanbankingnews.com - August 14 at 6:06 AM
|NeuroDerm Ltd. (NASDAQ:NDRM) Receives Average Rating of "Hold" from Brokerages|
www.americanbankingnews.com - August 11 at 6:18 PM
|NeuroDerm Announces Second Quarter 2017 Financial Results|
finance.yahoo.com - August 4 at 6:15 AM
|Roth Capital Downgrades NeuroDerm Ltd. (NDRM) to Neutral|
www.americanbankingnews.com - August 2 at 8:44 AM
|NeuroDerm Announces Extraordinary General Meeting of Shareholders to Approve Acquisition by Mitsubishi Tanabe Pharma Corporation|
finance.yahoo.com - August 2 at 6:14 AM
|NeuroDerm (NDRM) Catches Eye: Stock Gains 15.5% in Session - Nasdaq|
www.nasdaq.com - July 27 at 4:43 AM
|Featured Company News - NeuroDerm to be acquired by Mitsubishi Tanabe Pharma Corp.|
finance.yahoo.com - July 27 at 4:43 AM
|NeuroDerm (NDRM) Agrees to be Acquired by Japan's Mitsubishi Tanabe Pharma for $1.1B|
www.streetinsider.com - July 26 at 4:02 AM
|NeuroDerm Ltd. (NDRM) Set A New High After Bought By Mitsubishi Tanabe Pharma|
www.rttnews.com - July 26 at 4:02 AM
|NeuroDerm (NDRM) Catches Eye: Stock Gains 15.5% in Session|
finance.yahoo.com - July 26 at 4:01 AM
|Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm - TheStreet.com|
www.thestreet.com - July 25 at 6:04 AM
|NeuroDerm Ltd. (NDRM) Has Leaped To A New High After Merger - Nasdaq|
www.nasdaq.com - July 25 at 6:04 AM
|Japan's Nikkei inches up, caught in tight range before Fed meeting|
finance.yahoo.com - July 25 at 6:04 AM
|Aussie stocks lead a rebound for Asian markets as dollar steadies|
finance.yahoo.com - July 25 at 6:04 AM
|Nikkei edges down before Fed; Topix ends below key technical level|
finance.yahoo.com - July 25 at 6:04 AM
|Neuroderm Ltd (NDRM) Downgraded by Raymond James Financial, Inc. to "Market Perform"|
www.americanbankingnews.com - July 24 at 2:52 PM
|NeuroDerm To Be Bought By Japan's Mitsubishi Tanabe Pharma For $1.1 Blm In Cash|
www.rttnews.com - July 24 at 7:10 AM
|NeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash|
finance.yahoo.com - July 24 at 7:10 AM
|Mitsubishi Tanabe Pharma to buy Israel's Neuroderm for $1.1 bln|
finance.yahoo.com - July 24 at 7:10 AM
|NeuroDerm Ltd. (NASDAQ:NDRM) Coverage Initiated at Deutsche Bank AG|
www.americanbankingnews.com - July 22 at 8:14 PM
|Deutsche Bank Starts Neuroderm Ltd (NDRM) at Buy - StreetInsider.com|
www.streetinsider.com - July 22 at 6:50 AM
|Market Limps Into Weekend|
finance.yahoo.com - July 22 at 6:50 AM
|NeuroDerm Ltd. (NASDAQ:NDRM) Receives Average Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - July 17 at 11:59 AM
|NeuroDerm Ltd. (NASDAQ:NDRM) Expected to Announce Earnings of -$0.48 Per Share|
www.americanbankingnews.com - July 10 at 2:15 PM
|Results of NeuroDerm's ND0612H Phase II Trial Presented in Oral Session at the 3rd Congress of the European Academy of Neurology|
feeds.benzinga.com - June 27 at 7:55 AM
|Firm Fighting Parkinson's Hails Reviews, Upgrade|
www.baystreet.ca - June 14 at 10:44 PM
|Gainers & Losers Of June 14: OMER, EPZM, ALXN, SBBP, GBT...|
www.finanznachrichten.de - June 14 at 10:44 PM
|NeuroDerm (NDRM) Design of ND0612 Phase III iNDiGO Efficacy ... - StreetInsider.com|
www.streetinsider.com - June 6 at 7:29 PM
|NeuroDerm (NDRM) Presents ND0612H Phase II Trial Results in Late-Breaking Poster at MDS Congress - StreetInsider.com|
www.streetinsider.com - June 6 at 12:25 AM
|NeuroDerm Presents ND0612H Phase II Trial Results in Late-Breaking Poster ...|
www.nasdaq.com - June 5 at 7:24 PM
|NeuroDerm CEO to Present at the Jefferies Global Healthcare Conference on June 7, 2017 - GlobeNewswire (press release)|
globenewswire.com - May 30 at 7:06 AM
|NeuroDerm (NDRM) Says ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at MDS Congress - StreetInsider.com|
www.streetinsider.com - May 24 at 6:53 PM
|NeuroDerm (NDRM) Says ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at MDS Congress|
www.streetinsider.com - May 24 at 10:29 AM
|NeuroDerm reports 1Q loss|
www.cnbc.com - May 11 at 9:28 AM
|NeuroDerm Ltd. (Nasdaq: NDRM) to Ring The Nasdaq Stock Market Opening Bell - Nasdaq|
www.nasdaq.com - April 22 at 6:11 PM
|Q4 2016 Neuroderm Ltd Earnings Release - Before Market Open|
biz.yahoo.com - March 30 at 7:05 PM
|NeuroDerm downgraded by Oppenheimer|
us.rd.yahoo.com - March 7 at 6:37 PM
NeuroDerm (NDRM) Chart for Thursday, October, 19, 2017